• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.接受针对新冠病毒病全剂量疫苗接种的B细胞恶性肿瘤患者血清阳性率低且中和率未达最佳水平。
Br J Haematol. 2021 Dec;195(5):706-709. doi: 10.1111/bjh.17836. Epub 2021 Sep 21.
2
Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.异源 ChAdOx1-BNT162b2 疫苗接种的免疫原性和疗效。
Nature. 2021 Dec;600(7890):701-706. doi: 10.1038/s41586-021-04120-y. Epub 2021 Oct 21.
3
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
4
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.2019冠状病毒病疫苗对慢性淋巴细胞白血病患者的疗效
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
5
Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.墨西哥海军人员中两剂BNT162b2 mRNA新冠疫苗加一剂ChAdOx1-S加强针的免疫原性
Viruses. 2024 Apr 1;16(4):551. doi: 10.3390/v16040551.
6
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.多发性骨髓瘤完全接种疫苗患者对SARS-CoV-2的细胞反应各异。
Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19.
7
Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia.免疫性血小板减少症患者接种抗SARS-CoV-2疫苗的安全性
Br J Haematol. 2021 Dec;195(5):703-705. doi: 10.1111/bjh.17813. Epub 2021 Aug 31.
8
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.慢性淋巴细胞白血病患者在接种新冠疫苗期间停用3周布鲁顿酪氨酸激酶抑制剂与继续使用的对比研究（IMPROVE试验）：一项随机、开放标签的优效性试验
Lancet Haematol. 2025 Apr;12(4):e294-e303. doi: 10.1016/S2352-3026(25)00008-0.
9
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.浆细胞疾病患者接种第一剂和第二剂BNT162b2 mRNA或ChAdOx1 nCoV-19新冠疫苗后的血清学反应：宿主和疾病因素的影响
Br J Haematol. 2022 Feb;196(3):e21-e26. doi: 10.1111/bjh.17864. Epub 2021 Oct 10.
10
Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.当在丹麦将第一剂 ChAdOx1 疫苗与随后的 mRNA 疫苗相结合时，针对 SARS-CoV-2 感染、住院和死亡的疫苗有效性：一项全国范围内基于人群的队列研究。
PLoS Med. 2021 Dec 17;18(12):e1003874. doi: 10.1371/journal.pmed.1003874. eCollection 2021 Dec.

引用本文的文献

1
Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.与mRNA疫苗相比，ChAdOx1-S（AZD1222）疫苗接种后造血细胞移植受者体内的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）中和抗体反应保留得更多。
Br J Haematol. 2024 Dec;205(6):2206-2218. doi: 10.1111/bjh.19874. Epub 2024 Nov 17.
2
Chimeric antigen receptor-T-cell therapies going viral: latent and incidental viral infections.嵌合抗原受体-T 细胞疗法的病毒问题：潜伏性和偶发性病毒感染。
Curr Opin Infect Dis. 2024 Dec 1;37(6):526-535. doi: 10.1097/QCO.0000000000001066. Epub 2024 Oct 3.
3
COVID-19 vaccinated children, adolescents, and young adults with acute lymphoblastic leukemia show spike reactive antibodies and multifunctional T-cells.接种过新冠疫苗的急性淋巴细胞白血病儿童、青少年和年轻成人表现出刺突反应性抗体和多功能T细胞。
Int J Cancer. 2024 Dec 15;155(12):2190-2200. doi: 10.1002/ijc.35096. Epub 2024 Jul 15.
4
Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy.造血细胞移植或 CAR-T 细胞治疗后血液系统恶性肿瘤患者的疫苗接种计划建议和更新。
Transpl Infect Dis. 2023 Nov;25 Suppl 1(Suppl 1):e14109. doi: 10.1111/tid.14109. Epub 2023 Jul 29.
5
Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination.B 细胞血液恶性肿瘤患者对 SARS-CoV-2 的体液和细胞反应随着连续接种疫苗而改善。
Br J Haematol. 2023 Sep;202(6):1091-1103. doi: 10.1111/bjh.18962. Epub 2023 Jul 4.
6
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.成年癌症患者对新冠病毒疫苗全程接种和加强针的体液免疫反应受损，尤其是正在接受积极治疗的血液系统癌症患者：一项系统评价和荟萃分析。
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
7
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.免疫原性和与血液恶性肿瘤患者在接种 SARS-CoV-2 疫苗和加强针后免疫反应受损相关的风险：一项更新的荟萃分析。
Blood Cancer J. 2022 Dec 23;12(12):173. doi: 10.1038/s41408-022-00776-5.
8
Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.接受 BNT162b2 新冠疫苗第三剂加强针对于慢性淋巴细胞白血病患者的免疫原性：对治疗选择的影响。
Ann Hematol. 2022 Dec;101(12):2711-2717. doi: 10.1007/s00277-022-05003-6. Epub 2022 Oct 22.
9
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis.异基因造血干细胞移植（HSCT）或嵌合抗原受体（CAR）T细胞治疗受者中COVID-19疫苗接种的血清学反应及安全性：一项系统评价和荟萃分析
Exp Hematol Oncol. 2022 Aug 16;11(1):46. doi: 10.1186/s40164-022-00299-6.
10
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.一项系统评价和荟萃分析：成人血液恶性肿瘤患者对 SARS-CoV-2 疫苗首剂和第 2 剂的免疫应答。
Int Immunopharmacol. 2022 Sep;110:109046. doi: 10.1016/j.intimp.2022.109046. Epub 2022 Jul 12.

本文引用的文献

1
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.巴尼韦单抗/依特司韦单抗在轻中度 COVID-19 中的应用。
N Engl J Med. 2021 Oct 7;385(15):1382-1392. doi: 10.1056/NEJMoa2102685. Epub 2021 Jul 14.
2
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma.淋巴瘤患者接种新型冠状病毒疫苗后的抗体反应。
Lancet Haematol. 2021 Aug;8(8):e542-e544. doi: 10.1016/S2352-3026(21)00199-X. Epub 2021 Jul 2.
3
BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.BNT162b2 COVID-19 疫苗在血液恶性肿瘤患者中的有效性显著降低。
Am J Hematol. 2021 Oct 1;96(10):1195-1203. doi: 10.1002/ajh.26284. Epub 2021 Jul 14.
4
Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients.抗 CD20 治疗后的疫苗反应：905 例患者的系统评价和荟萃分析。
Blood Adv. 2021 Jun 21;5(12):2624-2643. doi: 10.1182/bloodadvances.2021004629.
5
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
6
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
7
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2，一种中和抗体鸡尾酒疗法，用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
8
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
9
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
10
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.血液系统恶性肿瘤合并 COVID-19 患者的结局：对 3377 例患者的系统评价和荟萃分析。
Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.

Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.

作者信息

Fox Thomas A, Kirkwood Amy A, Enfield Louise, O'Reilly Maeve, Arulogun Suzanne, D'Sa Shirley, O'Nions Jenny, Kavi Janki, Vitsaras Evan, Townsend William, Burns Siobhan O, Gohil Satyen H, Cwynarski Kate, Thomson Kirsty J, Noursadeghi Mahdad, Heyderman Robert S, Rampling Tommy, Ardeshna Kirit M, McCoy Laura E, Morris Emma C

机构信息

UCL Institute of Immunity and Transplantation, University College London, London, UK.

Department of Clinical Haematology, University College London Hospitals NHS Foundation Trust, London, UK.

出版信息

Br J Haematol. 2021 Dec;195(5):706-709. doi: 10.1111/bjh.17836. Epub 2021 Sep 21.

DOI:10.1111/bjh.17836
PMID:34545952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8653163/
Abstract
摘要